Abstract 426P
Background
The support for caregivers (CG) of patients with cancer is an essential factor for maintaining the safety and continuity of palliative chemotherapy. Because of insufficient knowledge regarding their QOL, there are no durable strategies for supporting CGs during the treatment.
Methods
We aimed to assess the QOL of the CGs of patients with cancer undergoing palliative chemotherapy. This single-institution, prospective, observational study was approvedby the institutional review board of Ina Central Hospital on July 20th 2016. Total 102 patients undergoing palliative chemotherapy (64 male and 38 female patients; mean age 68.8 years) and their CGs (30 maleand 72 female; mean age 64.3 years) were included. The primary lesions in the patients were pancreatic in 30, colorectal in 21, stomach or duodenal in 21, oesophageal in 18, and biliary in 12. We used EORTC QL-C-30 to assess the QOL of patients and CGs at the beginning of the first-line chemotherapy. A total of 29 of 102 pairs of patients and CGs were assessed at the beginning of the first and second-line chemotherapies. According to a formula incorporating measures of clinical symptoms and comprehensive scales of physical function (PF), role function (RF), emotional function (EF), cognitive function (CF), and social function. In addition, a summary score (SS) and a global health scale (GHS) on QOL were computed using comprehensive scales.
Results
All the parameters assessed in CGs yielded higher values than those for patients; however, EF and CF did not show significant differences between patients and CGs. Among longitudinal observed pairs, discrepancies in GHS and SS between patients and CGs were identified in 38 % and 34%, respectively. Those CGs who did not demonstrate an improvement in GHS compared with those who showed an improvement in this parameter had lower PF and RF values at the beginning of the treatment.
Conclusions
Even at the beginning of the treatment, the CGs of patients with cancer undergoing palliative chemotherapy showed impairment in daily QOL. In addition, emotional and cognitive functions were impaired as much as patients. CGs with physical difficulty and role function impairment in family should be monitored for worsening of their QOL during the course of treatment.
Clinical trial identification
Editorial acknowledgement
This has been edited for English language, grammar, punctuation, and spelling by Enago, the editing brand of Crimson Interactive Pvt. Ltd under Normal Editing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract